Drug intelligence / Profile preview

dinotefuran

Development stage
Unknown
Lead developer
Mitsui Chemicals
Modality
Small Molecules
Administration
Topical
01

Overview

Dinotefuran is a third-generation neonicotinoid insecticide of the furanicotinyl subclass, discovered and developed by Mitsui Chemicals. It features a unique tetrahydrofuran ring structure that distinguishes it from first- and second-generation neonicotinoids containing chloropyridine or chlorothiazole rings. Dinotefuran acts as an agonist of insect nicotinic acetylcholine receptors (nAChRs) in the central nervous system, causing continuous overstimulation of neurons, which leads to rapid feeding cessation, paralysis, and death. It is highly systemic, exhibiting translaminar and contact activity, and is widely used in agriculture to control sucking and chewing pests (such as aphids, whiteflies, thrips, and leafhoppers). In veterinary medicine, it is utilized as a topical ectoparasiticide (often in combination with pyriproxyfen and/or permethrin under brand names like Vectra and Vectra 3D) to prevent and treat flea and tick infestations in dogs and cats.

Brand names
AlbarinAlucionCertadorClaretDinnoDinoforceDinogardDinosun RangerDinotrexDominatorDynozineMikeblockSafariScorpionStarkleTenchuTranstectVectraVectra 3DVectra3DVectra-3DVectra FelisVenomZeusZylam
Other names
1-methyl-2-nitro-3-((tetrahydrofuran-3-yl)methyl)guanidine1-methyl-2-nitro-3-[(3-tetrahydrofuryl)methyl]guanidine1-methyl-3-nitro-2-[(tetrahydrofuran-3-yl)methyl]guanidine2-methyl-1-nitro-3-[(tetrahydro-3-furanyl)methyl]guanidineN''-methyl-N-nitro-N'-[(tetrahydro-3-furanyl)methyl]guanidinenidinotefuran
02

Targets

Nicotinic Acetylcholine Receptor

Beyond the preview

Go deeper on dinotefuran.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dinotefuran.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call